Compare · ATXI vs RLMD
ATXI vs RLMD
Side-by-side comparison of Avenue Therapeutics Inc. (ATXI) and Relmada Therapeutics Inc. (RLMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATXI and RLMD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- RLMD is the larger of the two at $600.0M, about 40.4x ATXI ($14.8M).
- Over the past year, ATXI is up 0.0% and RLMD is up 604.9% - RLMD leads by 604.9 points.
- RLMD has hit the wire 2 times in the past 4 weeks while ATXI has been quiet.
- RLMD has more recent analyst coverage (13 ratings vs 0 for ATXI).
- Company
- Avenue Therapeutics Inc.
- Relmada Therapeutics Inc.
- Price
- $0.42-50.37%
- $5.71-4.03%
- Market cap
- $14.8M
- $600.0M
- 1M return
- +0.00%
- -23.10%
- 1Y return
- +0.00%
- +604.94%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 13
Avenue Therapeutics Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.
Relmada Therapeutics Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Latest ATXI
- SEC Form 10-Q filed by Avenue Therapeutics Inc.
- SEC Form 10-K filed by Avenue Therapeutics Inc.
- Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
- Amendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.
- Large owner Fortress Biotech, Inc. was granted 111,209 shares, increasing direct ownership by 34% to 439,733 units (SEC Form 4)
- Avenue Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form EFFECT filed by Avenue Therapeutics Inc.
- SEC Form POS AM filed by Avenue Therapeutics Inc.
- SEC Form RW filed by Avenue Therapeutics Inc.
Latest RLMD
- Relmada Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
- SEC Form S-3ASR filed by Relmada Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Relmada Therapeutics Inc.
- Relmada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Relmada Therapeutics Inc.
- Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
- Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
- SEC Form DEFA14A filed by Relmada Therapeutics Inc.